Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOD001 phase 2b study in previously treated AL amyloidosis with persistent cardiac dysfunction
2015-004318-14Phase 2Terminated
- Sponsor
- Prothena Corporation
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in light-chain amyloidosis comparing NEOD001 with Placebo (2 arms). Primary endpoints: NT-proBNP best response and Change from baseline to 12 months in SF-36v2 Physical Component Score. Started Nov 2015; status: terminated.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2015-004318-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004318-14.